Cargando…
A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM)
BACKGROUND: Individuals who receive allogeneic hematopoietic cell transplant (allo-HCT) are immunocompromised and at high risk of pneumococcal infections, especially in the months following transplant. This study evaluated the safety and immunogenicity of V114 (VAXNEUVANCE; Merck, Sharp & Dohme...
Autores principales: | Wilck, Marissa, Cornely, Oliver A, Cordonnier, Catherine, Velez, Juan Diego, Ljungman, Per, Maertens, Johan, Selleslag, Dominik, Mullane, Kathleen M, Nabhan, Samir, Chen, Qiuxu, Dagan, Ron, Richmond, Peter, Daus, Caroline, Geddie, Kateasha, Tamms, Gretchen, Sterling, Tina, Patel, Shrita M, Shekar, Tulin, Musey, Luwy, Buchwald, Ulrike K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573722/ https://www.ncbi.nlm.nih.gov/pubmed/37338158 http://dx.doi.org/10.1093/cid/ciad349 |
Ejemplares similares
-
P07 A Phase 3 randomized, double-blind, comparator-controlled study to evaluate safety, tolerability and immunogenicity of V114 pneumococcal vaccine in haematopoietic cell transplant recipients (PNEU-STEM)
por: Wilck, Marissa, et al.
Publicado: (2023) -
P1576: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, COMPARATOR-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF V114 PNEUMOCOCCAL VACCINE IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS (PNEU-STEM)
por: Wilck, M., et al.
Publicado: (2022) -
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study
por: Quinn, Charles T., et al.
Publicado: (2022) -
Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU)
por: Severance, Randall, et al.
Publicado: (2021) -
Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18–49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors
por: Hammitt, Laura L., et al.
Publicado: (2023)